Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for MS

ConditionMultiple Sclerosis

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

AgeNot listed

SponsorThe Foundation for Orthopaedics and Regenerative Medicine

About this trial

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of multiple sclerosis

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of Multiple Sclerosis

Understanding and willingness to sign a written informed consent document

Disqualifiers

Active infection

Active cancer

Chronic multisystem organ failure

Pregnancy

Trial design

Design model

Single group

Treatments tested in this trial

AlloRx
Biological/Vaccine
cultured allogeneic adult umbilical cord derived mesenchymal stem cells

Treatment groups

15 Participants

are divided into 1 treatment group

Group A: Treatment GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Safety (adverse events)

Clinical monitoring of possible adverse events or complications

Time frame

Four year follow-up

Secondary outcomes

Efficacy: Kurtzke Expanded Disability Status Scale (EDSS)

EDSS is a scale to evaluate the function of the central nervous system. It will be completed for each follow up point

Time frame

Four year follow-up

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

The Foundation for Orthopaedics and Regenerative Medicine

Lead sponsor

Source ClinicalTrials.gov

Apply now